Latest Lead News

Almonty Industries has released an updated JORC technical report for its Sangdong Tungsten Mine, affirming Phase I production commencement in late 2025 and outlining plans for a fully permitted Phase II expansion to double throughput.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Ventia has expanded its partnership with NBN Co through a $280 million contract amendment to upgrade fibre infrastructure in the Australian Capital Territory, marking a strategic geographic expansion.

Kingston Resources has received the first $50 million payment from the sale of its Misima Gold Project, bolstering its balance sheet and enabling a strategic pivot towards expanding its Australian copper operations.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.

Australian Strategic Materials Limited (ASM) reminds eligible shareholders that its underwritten Share Purchase Plan closes on 17 July 2025, offering shares at a 20% discount. The plan is underwritten to $3 million by Canaccord Genuity, aiming to bolster ASM’s capital base.

Argosy Minerals has completed a $2 million capital raising led by Evolution Capital, following an ASX inquiry into recent trading activity. The company affirmed the materiality of the placement and its compliance with continuous disclosure rules.

Lowell Resources Fund updates its estimated FY25 dividend to AUD 0.0274 per unit with a partly franked component, alongside a revised distribution reinvestment plan price at a 10% discount.

Bryah Resources has lodged a formal application with the Takeovers Panel alleging breaches of takeover laws by shareholders linked to GBA Capital and Yonglu Yu, amid a looming boardroom showdown.

Brightstar Resources has launched its second phase of drilling at the Yunndaga deposit, aiming to expand and refine its gold resource as part of a fast-tracked development plan at the Menzies Hub.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.

Ausgold Limited has raised A$35 million through a well-supported placement to accelerate its Katanning Gold Project in Western Australia towards a final investment decision.